TTX

TTRATHERIX FPO [TTX]
Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical devices in the areas of bone regeneration, tissue spacing, tissue regeneration, and precision medicine applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.
Healthcare · ASX Small Cap
$7.0600 -1.9%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-03-16
Get alerts when TTX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track TTX — Free

Active Signals

Bullish Signals

  • Golden cross just fired — the short-term trend is overtaking the long-term, which is classically bullish
  • Above-average volume (1.7x) on a red day — sellers in control
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Trading above the 200-day average — the long-term trend is on your side
  • Strong cash runway (58 quarters)
  • 4C filed 2026-07-21
  • Very high P/S ratio (98.5x)
  • Strong revenue growth (+314%)
  • EPS estimates revised upward (+10pts)
  • CANSLIM S: Tight float (24%)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 93% over the past year (excluding last month)
  • Revenue growing at +314% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.66%/day)
  • RBA hiking (-3pts)

Risk Signals

  • Stochastic is stretched into overbought — could need a breather
  • Deeply negative margins (-241%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about TTX
"What's driving TTX today?" "How does TTX compare to peers?" "Key risks for TTX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Tetratherix Ships First US Polymer, Revenue Begins
NONE Application for quotation of securities - TTX
NONE Results Presentation 2026
LOW Appendix 4E and Annual Report 2026
LOW Quarterly Activities/Appendix 4C Cash Flow Report

Recent ASX Announcements

2026-08-30 Tetratherix Ships First US Polymer, Revenue Begins
2026-08-24 Application for quotation of securities - TTX
2026-08-20 Results Presentation 2026
2026-08-19 Appendix 4E and Annual Report 2026 PRICE SENSITIVE
2026-07-21 Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE

Key Metrics

$380.4M
Market Cap
29K
Avg Volume
1.7x
Vol Ratio
$3.09 — $8.08
52-Week Range
N/A
Short Interest
20 qtrs
Cash Runway
-31.1%
ROE
-241.4%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 24%
LLeader vs LaggardpassRS: 9
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:TTX vs REGTTX vs CANTTX vs BIT
Scout Pro — Deeper Analysis for TTX
Try Pro free for 30 days
Share this analysis

Track TTX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required